| abstract |
It is an object to provide a novel triazinone compound which has an inhibitory activity on a T-type voltage-dependent calcium channel, and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. A novel triazinone compound of Formula (I): nwherein each substituent in the formula is defined in detail in the description, R 4 means a hydrogen atom, or a C 1-6 alkoxy group, etc., L 1 and L 2 each independently mean a single bond, or NR 2 , etc., L 3 means a C 1-6 alkylene group, etc., A means a C 6-14 aryl group or a 5 to 10-membered heteroaryl group which may be substututed, B means a C 3-11 cycloalkylene group, etc., D means a C 6-14 aryl amino group or a 5 to 10-membered heteroaryl group which may be substituted, etc., a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, or the pharmaceutically acceptable salt. |